Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RedHill Biopharma ( (RDHL) ) has provided an update.
On April 30, 2026, RedHill Biopharma reported new in vitro data showing that its next-generation oral candidate RHB-204 achieved Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy comparable to its predecessor RHB-104, in both spot and phage assays across multiple MAP strains. The results were obtained using lower doses of two active ingredients than in RHB-104, suggesting potential for reduced toxicity and improved tolerability.
The company plans a Phase 2 trial of RHB-204 in a specifically defined MAP-positive Crohn’s disease population, building on prior Phase 3 success of RHB-104, which in past results was 64% more effective than standard of care alone at inducing clinical remission at week 26. With extensive regulatory designations, long patent protection, and a Crohn’s disease market projected to grow from $13.6 billion in 2024 to about $19.1 billion in 2033, RedHill is pursuing non-dilutive funding and partnerships to advance RHB-204, positioning it as a potentially transformative oral therapy in a segment where many patients fail or lose response to existing biologics.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on oral, proprietary, small-molecule therapies targeting gastrointestinal and infectious diseases. The company’s pipeline includes MAP‑targeted drug candidates such as RHB-104 and its next‑generation formulation RHB-204, aimed at treating Crohn’s disease and related indications in large, growing global markets.
Average Trading Volume: 39,318
Technical Sentiment Signal: Sell
Current Market Cap: $5.3M
Learn more about RDHL stock on TipRanks’ Stock Analysis page.